LIVE Today Foundation | ImpediMed

Proud Partner of the LIVE Today Foundation

The LIVE Today mission is to provide free compression garments to under-resourced cancer patients and survivors living with lymphedema. ImpediMed and the LIVE Today Foundation is focused on raising awareness of cancer-related lymphedema and providing patients and healthcare professionals the resources and tools needed to manage the condition on through survivorship.

Learn More about the LIVE Today Foundation

Dr. Sheri Prentiss: A Life of Service

Dr. Sheri is an occupational and environmental physician who was diagnosed with cancer in 2008, followed by lymphedema. As the founder of the LIVE Today foundation, Dr. Sheri has focused her efforts as a breast cancer patient advocate to bring attention to the chronic condition of lymphedema and provide under-resourced patients and cancer survivors the resources they will need to manage the debilitating condition.

Watch Dr. Sheri: A Life of Service

WATCH NOW

Lymphedema Awareness and the LIVE Today Foundation Partnership on NBC LX

WATCH NOW

The Life-Changing Impact of Lymphedema after Cancer

The risk of developing post-cancer lymphedema is very real. In fact, 1 in 3 at-risk cancer survivors will develop lymphedema as part of cancer survivorship1. The emotional and psychological impact of a lymphedema diagnosis can be devastating to patients who have battled and beaten cancer.

Watch and learn more from recent panel discussion, Breast Cancer Survivorship, Lymphedema, and Preserving the Whole Patient.

WATCH NOW

Lymphedema Treatment, Therapy & Prevention

Cancer-related lymphedema is Not Curable, but it is Preventable

Symptoms for cancer-related lymphedema usually appear within the first 3 years after cancer treatment2. To avoid chronic, lifelong lymphedema, cancer patients must begin testing early – before the condition becomes irreversible.

find a provider

Monitor & Manage Cancer-Related Lymphedema

Test

After cancer surgery, it is recommended that patients adhere to a lymphedema prevention protocol which includes periodic testing with SOZO to establish a baseline and detect the presence of secondary lymphedema.

Trigger

Clinical evidence supports that an elevated L-Dex score of 6.5 or more from the baseline serves as a “trigger” to indicate that the patient should be evaluated and treatment intervention should begin3.

Treat

Treatment for patients diagnosed with early lymphedema, including standard compression has been shown to reduce the progression of lymphedema by 95% in breast cancer patients4.

1. At-risk cancers include breast, melanoma, and gynecologic cancers. Shaitelman SF, et al. Recent Progress in the Treatment and Prevention of Cancer-Related Lymphedema. CA Cancer J Clin 2015;65:55-81.

2. Ridner SH, et al. A Randomized Trial Evaluating Bioimpedance Spectroscopy Versus Tape Measurement for the Prevention of Lymphedema Following Treatment for Breast Cancer: Interim Analysis. Ann Surg Oncol 2019; https://doi.org/10.1245/s10434-019-07344-5.

3. Ridner SH, et al. A Randomized Trial Evaluating Bioimpedance Spectroscopy Versus Tape Measurement for the Prevention of Lymphedema Following Treatment for Breast Cancer: Interim Analysis. Ann Surg Oncol 2019; https://doi.org/10.1245/s10434-019-07344-5.

4. Shah C, et al. Bioimpedance Spectroscopy for Breast Cancer Related Lymphedema Assessment: Clinical Practice Guidelines. The Breast Journal 2016;DOI: 10.1111/tbj.12647